Arrowhead Research | ARWR - Equity Capital And Reserves


Arrowhead Research reported $613.98M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Agios Pharmaceuticals USD 1.11B 84M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
Anika Therapeutics USD 133.9M 9.56M Mar/2026
Arrowhead Research USD 613.98M 45.56M Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Incyte USD 5.62B 455.37M Mar/2026
Ionis Pharmaceuticals USD 491.41M 2.32M Mar/2026
Ligand Pharmaceuticals USD 997.32M 19.89M Mar/2026
Merck USD 45.88B 6.73B Mar/2026
Moderna USD 7.41B 1.24B Mar/2026
Nektar Therapeutics USD 89.83M 4.75M Dec/2025
Novartis USD 38.93B 7.2B Mar/2026
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
TG Therapeutics USD 583.13M 64.89M Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026
Xencor USD 515.63M 119.95M Mar/2026